These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22464311)

  • 1. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature.
    Calabrò F; Albers P; Bokemeyer C; Martin C; Einhorn LH; Horwich A; Krege S; Schmoll HJ; Sternberg CN; Daugaard G
    Eur Urol; 2012 Jun; 61(6):1212-21. PubMed ID: 22464311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
    Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
    Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current pharmacotherapy for testicular germ cell cancer.
    Alsdorf W; Seidel C; Bokemeyer C; Oing C
    Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for advanced germ cell tumors.
    Kondagunta GV; Motzer RJ
    J Clin Oncol; 2006 Dec; 24(35):5493-502. PubMed ID: 17158534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.
    Lawrence NJ; Chan H; Toner G; Stockler MR; Martin A; Yip S; Wong N; Yeung A; Mazhar D; Pashankar F; Frazier L; McDermott R; Walker R; Tan H; Davis ID; Grimison P;
    BMC Cancer; 2018 Aug; 18(1):854. PubMed ID: 30157803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.
    Kawai K; Akaza H
    Cancer Sci; 2010 Jan; 101(1):22-8. PubMed ID: 19922501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
    Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
    Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
    Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current medical management of patients with poor-risk metastatic germ-cell tumors.
    Albany C
    Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
    Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
    Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical treatment of advanced testicular cancer.
    Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
    JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
    Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
    Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based treatment for advanced germ cell tumor of the testis with a case illustration.
    Lin CK; Liu HT
    J Chin Med Assoc; 2010 Jul; 73(7):343-52. PubMed ID: 20688298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis.
    Ramani VA; Grey BR; Addla SK; Dunham MP; Sangar VK; Clarke NW
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):247-52. PubMed ID: 18093814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
    J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
    Bokemeyer C
    Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.